South Dakota § 34-20B-20 Depressants specifically included in Schedule III.

South Dakota Statutes

§ 34-20B-20 — Depressants specifically included in Schedule III.

South Dakota § 34-20B-20

Title 34PUBLIC HEALTH AND SAFETY

Ch. 34-20DRUGS AND SUBSTANCES CONTROL

This text of South Dakota § 34-20B-20 (Depressants specifically included in Schedule III.) is published on Counsel Stack Legal Research, covering South Dakota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

S.D. Codified Laws § 34-20B-20 (2026).

Text

Any material, compound, mixture, or preparation is included in Schedule III that contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:

(1)Any substance that contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances that are specifically listed in other schedules;

(2)Chloral betaine;

(3)Chloral hydrate;

(4)Chlorhexadol;

(5)Lysergic acid;

(6)Lysergic acid amide;

(7)Methyprylon;

(8)Sulfondiethylmethane;

(9)Sulfonethylmethane;

(10)Sulfonmethane;

(11)Amobarbital, pentobarbital, and secobarbital in suppository dosage form;

(12)Gamma hydroxy butyrate;

(13)Dronabinol in sesame oil and

Free access — add to your briefcase to read the full text and ask questions with AI

Any material, compound, mixture, or preparation is included in Schedule III that contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system: (1) Any substance that contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances that are specifically listed in other schedules; (2) Chloral betaine; (3) Chloral hydrate; (4) Chlorhexadol; (5) Lysergic acid; (6) Lysergic acid amide; (7) Methyprylon; (8) Sulfondiethylmethane; (9) Sulfonethylmethane; (10) Sulfonmethane; (11) Amobarbital, pentobarbital, and secobarbital in suppository dosage form; (12) Gamma hydroxy butyrate; (13) Dronabinol in sesame oil and encapsulated in a gelatin capsule in a drug product approved for marketing by the United States Food and Drug Administration; (14) Buprenorphine; (15) Embutramide; (16) Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benzonitrile], including its salts, isomers, and salts of isomers.

Legislative History

SL 1970, ch 229, § 8 (c) (1); SDCL Supp, § 39-17-63; SL 1973, ch 260; SL 1979, ch 238, § 2; SL 1980, ch 240, § 1; SL 1992, ch 245, § 2; SL 1993, ch 247, § 4; SL 1999, ch 174, § 1; SL 2000, ch 170, § 2; SL 2003, ch 183, § 3; SL 2007, ch 194, § 2, eff. Feb. 1, 2007; SL 2014, ch 165, § 2, eff. Feb. 10, 2014; SL 2018, ch 203, § 4, eff. Feb. 8, 2018.